Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Canada NewsWire
LAVAL, QC, May 15, 2019
LAVAL, QC, May 15, 2019 /CNW Telbec/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced the voting results from its 2019 Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec.
Election of Directors
The detailed results of the votes for director nominees listed in the Management Information Circular dated March 18, 2019 (the "Circular") are as follows:
Director Nominees
| NUMBER OF SHARES
| PERCENTAGE OF VOTES CAST
|
FOR
| WITHHELD
| FOR
| WITHHELD
|
Daniel N. Chicoine
| 7,456,570
| 587,320
| 92.7%
| 7.3%
|
David A. Copeland
| 7,465,703
| 578,187
| 92.8%
| 7.2%
|
Anthony E. Dobranowski
| 7,476,684
| 567,206
| 92.9%
| 7.1%
|
John C. London
| 7,451,239
| 592,651
| 92.6%
| 7.4%
|
Dr. Jean-François Tremblay
| 7,483,476
| 560,414
| 93.0%
| 7.0%
|
Thomas Schlader
| 7,483,400
| 560,490
| 93.0%
| 7.0%
|
Appointment of External Auditors
Ernst and Young LLP were appointed as external auditors of the Corporation for the next year by a majority of the votes cast by the shareholders present, or represented by proxy, and the directors were authorized to determine their remuneration. The shareholders voted as follows:
Outcome
| NUMBER OF SHARES
| PERCENTAGE OF VOTES CAST
|
FOR
| WITHHELD
| FOR
| WITHHELD
|
Ernst & Young LLP appointed
| 7,796,409
| 597,104
| 92.9%
| 7.1%
|
Approval of Amendments to and Continuation of Crescita's Shareholder Rights Plan
The resolution to approve the amendments to and the continuation of Crescita's Shareholder Rights Plan, as described in the Circular, was approved by a majority of the votes cast by shareholders present at the meeting or by proxy, as follows:
Outcome
| NUMBER OF SHARES
| PERCENTAGE OF VOTES CAST
|
FOR
| WITHHELD
| FOR
| WITHHELD
|
Shareholder Rights Plan approved
| 7,415,592
| 628,298
| 92.2%
| 7.8%
|
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. For additional information, please visit www.crescitatherapeutics.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/crescita-therapeutics-announces-the-results-of-its-annual-general-and-special-meeting-of-shareholders-300850702.html
SOURCE Crescita Therapeutics Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/15/c5195.html
Investor Relations, Email: ir@crescitatx.comCopyright CNW Group 2019